Coccaro M, Bochicchio A M, Capobianco A M, Di Leo P, Mancino G, Cammarota A
Department of Medical Oncology, Ospedale Oncologico Regionale, Centro di Riferimento Oncologico della Basilicata (CROB), Rionero In Vulture (PZ), Italy.
Tumori. 2001 Sep-Oct;87(5):308-11. doi: 10.1177/030089160108700506.
Long-term central vein catheters have found clinical application in different fields of medicine and particularly in oncology. In fact, the continuous infusion of some drugs has become the standard treatment in a wide variety of cancers, but central vein catheters are not without risks. The authors report their experience with central vein catheters. From January 1,1998, to December 31, 1999, 98 central vein catheters were placed in neoplastic patients. Seventy-seven (78.6%) Groshong and 16 (16.3%) Port-a-cath catheters were used. The central vein catheters were placed under local anesthesia. Before placement of the central vein catheters, the patients were checked by chest X-ray and neck ultrasonography. The procedure was performed under fluoroscopic control. The central vein catheters were flushed periodically with normal saline solution and sodium heparin. Sterile transparent adhesive dressings were used to occlude the operative site. The median follow-up of patients was 9 catheter months (range, 1-24 months). There were a few early and late clinically evident complications. The early complications were dislodgement in 5 cases (5.1%). The late complications were: fibrin sleeve in 1 case (1.1%), thrombosis in 2 cases (2.1%) and skin infection in 4 cases (4.1%). The low prevalence of major complications related to implants and management of these supports an increased use in oncology.
长期中心静脉导管已在医学的不同领域,尤其是肿瘤学中得到临床应用。事实上,持续输注某些药物已成为多种癌症的标准治疗方法,但中心静脉导管并非没有风险。作者报告了他们使用中心静脉导管的经验。从1998年1月1日至1999年12月31日,98根中心静脉导管被置入肿瘤患者体内。使用了77根(78.6%)Groshong导管和16根(16.3%)植入式静脉输液港导管。中心静脉导管在局部麻醉下置入。在置入中心静脉导管之前,患者接受了胸部X线检查和颈部超声检查。该操作在荧光透视控制下进行。中心静脉导管定期用生理盐水和肝素钠冲洗。使用无菌透明粘性敷料封闭手术部位。患者的中位随访时间为9个导管月(范围1 - 24个月)。出现了一些早期和晚期临床明显的并发症。早期并发症为5例(5.1%)导管移位。晚期并发症为:1例(1.1%)形成纤维蛋白套,2例(2.1%)发生血栓形成,4例(4.1%)出现皮肤感染。与植入物相关的主要并发症发生率较低以及这些并发症的处理情况支持在肿瘤学中增加其使用。